Navigation Links
Multiple Sclerosis Patients to Benefit With AVONEX(R) Nurse Services Program

AVONEX can now be administered with a smaller needle, which can further advance patient comfort. The storage and transportation of AVONEX has been made even easier with the introduction of ambient storage for the AVONEX luer-lock prefilled syringe. A new AVOGRIP(TM) is available to aid patients in the administration of injections. These improvements are part of the company's efforts to improve patients' experience with AVONEX. In addition, AVONEX patients have shown significantly higher adherence rates than the other approved disease-modifying therapies (DMTs).(1)

AVONEX is the most prescribed treatment for relapsing forms of MS worldwide, with more than 130,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is marketed internationally in more than 90 countries.

AVONEX was the first treatment approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS; this use was approved in Europe in 2002 and in the U.S. in 2003. The most common side effects associated with AVONEX multiple sclerosis treatment are flu-like symptoms, including myalgia, fever, fatigue, headache, chills, nausea, vomiting, pain and asthenia.

AVONEX should be used with caution in patients with depression or other mood disorders and in patients with seizure disorders. AVONEX should not be used by pregnant women. Patients with cardiac disease should be closely monitored. Patients should also be monitored for signs of hepatic injury. Routine periodic blood chemistry and hematology tests are recommended during treatment with AVONEX. Rare cases of anaphylaxis have been reported

Source-IANS/N
'"/>




Page: 1 2

Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay $56.9 million to ... a claimant alleged to have suffered an arterial blood clot including stroke and heart ... Yasmin and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions ... health care costs. , Annually, more than 8.6 million adverse drug events ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
Breaking Medicine News(10 mins):Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... recovering from heart problems, but have depression take longer ... a treadmill stress test, according to a new study ... Dr. Joel W. Hughes, of Kent State University, Ohio, ... recover from the stress test have increased mortality risk. ...
... to naught. Apart from the ordeal of suffering a naughty child, ... an awfully expensive proposition for the parents and for the society ... to the parents, the NHS, social services and schools to the ... ,But the most part of the ordeal is faced by the ...
... currently on a visit to Riyadh, has declared that ... center for the All India Engineering Entrance Examination (AIEEE) ... of equivalence of degrees will cease to be a ... Muslim University Old Boys' Association (AMUOBA), which had organised ...
... Karen Johnstone, 28, was suffering from Deep Vein Thrombosis since ... away after doctors told her that she no longer suffered ... a blood clot that had formed in her legs moved ... her lungs. ,Kathy and Norman, Karen’s parents, absolutely devastated ...
... on the worries experienced by long-term survivors reveals the ... treatment//, a second cancer and a shortened life will ... the thoughts of approximately one-third of long-term, older-adult cancer ... Survivor Research Project reports. ,It may ...
... increases the concentration, abstract reasoning and verbal skills in ... must be interpreted with caution//. ,Mark Espeland ... Center in the US studied more than 7,000 older ... amount of alcohol have slightly higher levels of mental ...
Cached Medicine News:Health News:After Cancer Treatment Worry Continues – Researchers Find 2Health News:After Cancer Treatment Worry Continues – Researchers Find 3
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4
... statins for only five weeks at,400 mg/week lowered ... with similarly favorable effects on other,atherogenic lipids, NEW ... Isis Pharmaceuticals, Inc. announced new,results from its Phase ... presented today at the of Cardiology,Annual Scientific Session ...
... Only Illinois Site in Trial , CHICAGO, March ... adult stem cell therapy, Provacel™,experienced a lower number ... significant improvements in heart, lung and,global function compared ... Phase I study data presented at the American ...
Cached Medicine Technology:Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 2Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: